Entities

Becca Shmukler is a Partner at Laerdal Million Lives Fund, with healthcare-industry experience at the Advisory Board Company, Castlight Health and Rock Health. Novocuff’s July2024 issuer announcement names her board appointment; current board membership is not independently republished on its current team page.

Physician and Faro AI co-founder. Helped establish the company's platform for digital clinical study design and authoring.

SVP, Customer at Faro AI, a company developing AI and structured data infrastructure for clinical development.

Board Chair at Faro AI, a company developing AI and structured data infrastructure for clinical development. San Francisco operating partner at Polaris investing in healthcare services and products. The current manager biography confirms his Faro Health/Faro AI board affiliation and work with Foresight Mental Health and UpDoc. Formerly CEO of oDesk.

Financial Controller at Faro AI, a company developing AI and structured data infrastructure for clinical development.

Chief Commercial Officer at Faro AI, a company developing AI and structured data infrastructure for clinical development.

Faro AI co-founder and chief executive officer, developing structured data and AI infrastructure for clinical development.

Hatteras Venture Partners is a healthcare venture capital firm investing in biotechnology, medical devices and health technology. It backs companies from formation and seed-stage science through clinical development and commercial growth. The firm helps founders with company building, recruitment, regulatory and clinical planning, business development and follow-on financing.

Douglas Crawford is a scientist and life-science investor with a UCSF biochemistry PhD. Mission Bay Capital publishes him as managing director; March2026 ADV confirms Douglas Kingsley Crawford as managing director of the original manager and managing member of the FundII/FundIII advisers. He founded and manages the MBC BioLabs shared-laboratory network and the published biography also identifies his Mission BioCapital managing partner affiliation. Published laboratory and portfolio-company totals are historical programme claims, not personally invested capital.

Johannes Fruehauf, MD, is a QurAlis director and co-founder of Mission BioCapital, LabCentral and BioLabs. His background combines medical and entrepreneurial biotechnology work, with doctoral training in Heidelberg and postdoctoral research at Beth Israel Deaconess/Harvard.

Linda Eng is published as Mission Bay Capital office manager, supporting investment tracking, meetings and administration. Its undated biography also describes her business-management work at the QB3@953/MBC BioLabs laboratory incubator and earlier UCSF translational research programme management. She helped the venture fund during its formation while assisting Douglas Crawford, and later coordinated multicentre cancer-research activities. Historical outside project budgets are not venture fund capital or personal investments.

Peter D. Parker is published as a Mission Bay Capital venture partner in its undated directory. The biography describes his historical managing general partner affiliation with BioInnovation Capital, his cofounding of Cambridge BioLabs and LabCentral with Johannes Fruehauf, and earlier life-science investing at Ampersand Capital Partners. He was President and CEO of Cequent Pharmaceuticals from2006to2010 and studied at Columbia University. The undated BioInnovation title is historical context rather than proof of a currently independent adviser; he is distinct from unrelated Peter Parker names.

Robert Blazej is a biotechnology entrepreneur and investor published as a Mission Bay Capital partner. March2026 Awesome Enablers ADV corroborates Robert Glenn Blazej as principal of the FundIII adviser. He previously directed digital biotechnology and global scouting at Novozymes and co-founded Allopartis Biotechnologies, acquired by Novozymes in2013. His2006 joint UC Berkeley/UCSF bioengineering doctorate focused on microfluidic DNA-sequencing systems. External MBC BioLabs and Mission BioCapital affiliations remain separate.

Homecoming develops software for psychological screening and patient support in psychedelic therapy. Its current platform administers assessments, structures clinical interviews and drafts editable reports for clinician review. It helps clinics document treatment readiness and manage preparation and follow-up workflows.

Sensorium Therapeutics is a clinical-stage biotechnology company developing small-molecule medicines for central nervous system disorders. Its SensAI discovery platform combines artificial intelligence, natural-product chemistry, pharmacology and neuroscience to identify therapeutic candidates. Its pipeline includes programs for anxiety, drug-resistant epilepsy and cognitive impairment associated with neurodegenerative disease.

UC Davis Health Ventures is the university health system’s innovation and commercialization arm within the Innovation and Economic Development Office. It helps turn research in therapeutics, digital health, diagnostics and medical devices into products and companies through intellectual-property development, industry partnerships and a venture studio. Its Investing in the Future of Medicine program supports research translation, startup incubation and investments in aligned companies.

K. Ranga Krishnan is a ClavystBio director and senior adviser to the Rush University System for Health. He previously served as Rush Medical College dean and Rush’s chief executive, and earlier led Duke-NUS Graduate Medical School Singapore.

Kevin Lalande is listed by Santé Ventures as Founding Managing Director & Chief Investment Officer. Co-founded the firm in 2006 after Austin Ventures and McKinsey; trained in electrical engineering, business and artificial intelligence.

Physician publicly named as a PTX Capital teammate by investment analyst Daniel Antov. His precise investment or operating title is not disclosed in the cited primary source.

Publicly named PTX Capital teammate. Her precise investment or operating title is not disclosed in the cited primary source.

PTX Capital investment analyst and Johns Hopkins biomedical engineering PhD researcher. His research includes biomaterials and drug delivery, and Johns Hopkins announced his NSF Graduate Research Fellowship in 2025.

Baltimore investment firm founded by Matthew Hellauer, focused on healthcare, life sciences and technology that improves care. Its investments include AI infrastructure for clinical development, simulation for medical devices and technology-enabled care delivery. Public sources identify investment professionals and physician collaborators, with some team titles undisclosed.

PTX Capital founder and managing partner, also known as Matt Hellauer. Previously worked at Allen & Company from 2011 to 2021. Studied mathematics at Georgetown and earned an MBA at Harvard Business School.

PTX Capital venture partner and Johns Hopkins ophthalmologist working on AI and precision medicine. Founding director of the Wilmer Precision Ophthalmology Center of Excellence and publicly named PTX teammate.

biotx.ai develops causal AI and human-genetics analysis tools for drug discovery. It applies Mendelian randomization, colocalization and machine learning to genetic, disease and biomarker data to evaluate drug targets and estimate associations with clinical development outcomes. Its data and models are intended to help researchers prioritize targets and design clinical trials.

Ocama Partners is a private investment vehicle focused on advances in mental health through science, technology and therapy. Its investments include clinician-supervised behavioral health AI and biotechnology companies developing tools for drug discovery and therapeutic research.

Partner at Hoxton Ventures with software industry and venture investing experience.

Toyin Ajayi is co-founder and part-time gp at Coalition Operators. Alongside her work at Coalition, Toyin is the co-founder and CEO of Cityblock Health, a multibillion-dollar company delivering high-quality care to the most marginalized populations. She’s a physician by training, and has spent her career building solutions for people who’ve been left behind by the U.S. healthcare system. Toyin shares her hard-won insights on building in regulated industries and scaling complex teams and businesses. She’s especially helpful to founders navigating healthcare, education, and all things tech-enabled services. Outside company titles are attributed to the firm’s published biography, not automatically changed on external organizations.

Nell Brennan is director of finance at Valia Ventures, as listed in the firm's current team directory.

Riley Rodgers is venture partner at Valia Ventures, as listed in the firm's current team directory.

Omar Sebai is principal at Valia Ventures, as listed in the firm's current team directory.

Venture capital firm with offices in New York, San Francisco and London, investing from company formation through growth. Uses pre-seed, early-stage and opportunity strategies across sectors, including AI agents, healthcare AI, robotics, nuclear energy and aerospace. Its relevant portfolio includes Inner Logic, Built Robotics, Yutori, Valar Atomics and Relativity Space.

Khaled Jalanbo is managing partner at Valia Ventures, as listed in the firm's current team directory.

Inner Logic co-founder and chief robotics officer, and Johns Hopkins mechanical engineering associate professor. Leads research on image-guided interventions and autonomous surgical robots, including the Smart Tissue Autonomous Robot's animal-model research.

Inner Logic co-founder and chief technology officer, and Johns Hopkins computer science associate professor. Researches computer vision, AI-assisted medicine, simulation, mixed reality and medical robotics.

Inner Logic co-founder and chief executive officer, trained in medicine and neurosurgery at Dartmouth and Johns Hopkins. Builds AI and simulation infrastructure for procedural devices and surgical autonomy; also holds an MBA from Johns Hopkins Carey Business School.

Defined investor with experience in AI infrastructure, biotechnology, climate technology and portfolio operations. Previously worked in product marketing at Rafay Systems, helping commercialize GPU cloud and distributed AI inference infrastructure.

Defined venture partner with experience building investment practices at Prologis Ventures and GreatPoint Ventures. Founder of Public School Ventures and Stresswood and co-host of the Swimming with Allocators venture capital podcast.

Defined operating and venture partner and technology entrepreneur. Founded or co-founded startups including Visio, Netbot, Qpass and Medio; also a partner at Threshold Ventures. Supports founders on product strategy, commercial development and organizational growth.

Venture capital firm branded Defined, led by founding partner Mark Trevitt and investing from the earliest stages across the AI technology stack. Its focus spans foundation models, physical AI, robotics, computational biology, quantum computing and advanced hardware, with research and operating support for founders.

Defined venture partner with more than 25 years of technology investment and company-building experience. Previously a general partner at Rho Canada Ventures, with investment leadership experience at 3i Group and BDC Capital. Also co-founder and managing partner of True North Fund.

Builds neuroscience research partnerships between academia and industry.

Town Hall Ventures invests in and helps launch healthcare companies serving communities underserved by the US healthcare system. It backs venture and growth businesses in mental health, senior care, Medicaid, rural healthcare, cancer care and clinician productivity, including companies applying AI to care delivery and operations. Its Hatch team helps build new healthcare businesses.

Andy Slavitt is the published president of Qualified Health’s advisory board. He co-founded Town Hall Ventures and previously served as head of the Centers for Medicare and Medicaid Services and as a White House adviser on the COVID response. His public and private-sector experience centers on healthcare access, policy and delivery. The advisory role is distinguished from the company’s statutory board of directors.

David Whelan is publicly listed by Thyme Care as Board Member. The directory describes their outside affiliation as Founder & General Partner, Town Hall Ventures; that title is context, not an executive position at Thyme Care.

Meera Mani is a physician and Town Hall Ventures general partner listed in Qualified Health’s investor and adviser roster. She previously worked in McKinsey’s healthcare practice, including leadership on Medicaid. Her experience covers insurers, health systems, public agencies and healthcare investors, with a focus on care access and underserved populations. Existing Town Hall affiliations are preserved; no personal cash ticket is inferred. CHCF Innovation Fund adviser, physician and neuroscientist. Her own CHCF biography describes healthcare-AI, youth-mental-health and dementia investment experience, prior McKinsey healthcare leadership and Town Hall Ventures affiliation.

Chairman of Ovid Therapeutics’ Scientific and Clinical Advisory Board. A biomedical engineer and MIT Institute Professor known for drug delivery and tissue engineering research, and a founder of biotechnology companies. Robert S. Langer ScD is PureTech’s co-founder, non-executive director and R&D Committee member, and MIT’s David H. Koch Institute Professor. His biomedical engineering research covers drug delivery and tissue engineering, with extensive patents and licensing. He studied chemical engineering at Cornell and MIT; his existing Ovid scientific advisory identity and portrait are preserved. Robert Langer is published by aMoon as External Adviser. MIT biomedical engineering professor whose research concerns drug delivery, biotechnology and tissue engineering. This is an advisory or venture-partner affiliation; no employment or personal investment is inferred.

Bison Ventures principal with biomedical engineering and frontier technology investment experience. Previously spent five years at Braemar Energy Ventures. Interests include neuromorphic computing, regenerative medicine, spatial computing and environmental technologies. Educated at Brown, USC and Harvard Business School.

Bison Ventures principal with infrastructure and technology investment experience at G2 Venture Partners, Morgan Stanley Infrastructure Partners and Barclays. Holds degrees in operations research and financial engineering from Princeton, systems engineering from the University of Pennsylvania, and an MBA from Wharton.

Executive assistant and operations support professional at Bison Ventures with experience in finance, startups and arts institutions. Studied anthropology at the University of Michigan and history of art and curating at UCL.

Bison Ventures partner focused on technology-enabled biology and AI in the physical world. A biomedical engineer previously investing at Innovation Endeavors and leading TuneIn's global subscription business as senior vice president and general manager. Holds a biomedical engineering degree from Georgia Tech.

Bison Ventures founding partner and engineer with frontier technology investment experience at Cascade Asset Management and Altira Group. Previously worked in semiconductor manufacturing at Intel and solar photovoltaic technology development. Holds a Cornell materials science and engineering degree and a Kellogg MBA.

Early-stage venture capital firm investing in frontier science and deep technology, including AI in the physical world, robotics, computational biology, advanced hardware and climate technology. Founded by former Cascade Asset Management investors Tom Biegala and Ben Hemani, with a current San Francisco address. Its portfolio includes AI-enabled therapeutics, behavioral healthcare, autonomous systems and AI infrastructure.

Arkitekt Ventures is an early-stage venture capital firm investing in healthcare and life sciences companies that apply scientific advances and frontier technology to human health. Its investments span neurotechnology and brain-computer interfaces, AI for biology, mental health care, healthcare infrastructure and therapeutics.

Standard Model Biomedicine develops multimodal AI foundation models that combine genomic, radiology, pathology and longitudinal patient-record data into shared patient representations. Its models support research into disease progression and treatment response, and its Trial Front platform helps design and simulate clinical trials. It offers open-weight models and models deployed in partners’ secure computing environments.

Neuroscientist and venture investor with a PhD from Columbia University and an MBA from Harvard Business School. Founded Arkitekt Ventures to invest in healthcare and life sciences innovation.

Frank Williams co-founded Evolent Health and previously led the Advisory Board Company. Qualified Health publishes him among its investors and advisers, and SignalFire’s January2025 investment announcement explicitly names him as a participating angel. His background covers healthcare services, technology and public-company growth. Existing SignalFire-related identity and roles are preserved; Evolent board status is not treated as a Qualified Health board appointment. Frank Williams is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Co-Founder, Evolent Health. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Jerry Yang is the Founding Partner of AME Cloud Ventures, supporting entrepreneurs working on data, cloud computing, hardware and deep technology. He co-founded Yahoo in 1995 and served in executive and board capacities through 2012, helping establish relationships with Yahoo Japan and Alibaba. SignalFire’s own biography independently identifies him as AME’s founding partner, confirming reuse of this existing advisor profile. AME’s older outside board wording is not treated as proof of current 2026 appointments. This Yahoo founder is distinct from the retained HCVC investor with the same name.

Sooah Cho is a SignalFire partner focusing on health and life-sciences technology, with previous product and investment work at CVS Health, Devoted Health and Underscore VC. She led SignalFire’s January2025 Qualified Health investment and stated that she joined its board. The July2026 SEC filing independently identifies her as a statutory director. Existing SignalFire identity and affiliations remain preserved. Sooah Cho is named as a Doro Mind director in its March2026 FormD. She is a SignalFire partner focused on early-stage health and life-sciences technology; the board role does not imply a personal cash investment or full-time clinical employment.

Tom Peterson is chief executive officer of Blackbird Health, which he joined as CEO in 2023 after his family’s experience with its clinical model. SignalFire’s current biography identifies him as co-founder and former chief operating officer of Evolent Health, and describes prior leadership of the Advisory Board Company’s technology and consulting divisions. He studied at Harvard and earned a master’s degree in mental-health counseling at George Washington University. His existing SignalFire advisor identity and external role are preserved.

Juvena Therapeutics senior vice president of drug development, with experience developing antibodies, small molecules and cellular therapies at Harpoon Therapeutics, Astellas and Genentech.

Juvena Therapeutics senior vice president of clinical development. Physician and drug development executive with experience at Lilly, Procter & Gamble Pharmaceuticals, CV Therapeutics, Versartis and Eiger BioPharmaceuticals.

Juvena Therapeutics vice president of finance and operations, overseeing finance, people, technology and business operations. Previously held finance leadership roles at Genentech/Roche, Autodesk and Bio-Rad.

Juvena Therapeutics senior director of discovery and platform, with stem cell biology, bioinformatics and protein therapeutic screening expertise.

Juvena Therapeutics senior director of program management, with experience coordinating biologic and small molecule programs across research, clinical development, manufacturing and regulatory functions.

Juvena Therapeutics senior director of translational biology and pharmacology, with metabolic, hepatic, renal and ocular research experience. Previously led tissue regeneration discovery programs at Surrozen.

Juvena Therapeutics senior director of bioanalytical science, with biochemistry, immunology and protein engineering expertise, including protein expression and purification systems.

Bison Ventures founding partner and Juvena Therapeutics director. An engineer and investor focused on AI in the physical world, robotics, computational drug discovery and climate technology. Previously invested at Cascade Asset Management and Braemar Energy Ventures; earned engineering and engineering management degrees at Dartmouth.

Juvena Therapeutics independent director, also listed as Steven P. James in its financing announcement. Previously served as chief executive at Pionyr Immunotherapeutics, Labrys Biologics and KAI Pharmaceuticals.

Juvena Therapeutics independent director and former Genentech executive vice president, as identified in the company's current governance directory.

Juvena Therapeutics co-founder, chief scientific officer and director, overseeing research strategy, preclinical science and intellectual property. Has proteomics and systems biology research experience at UT Austin and Harvard.

Juvena Therapeutics chief executive and director, appointed in August 2026. Biotechnology executive with experience developing and commercializing medicines for rare and orphan diseases.

Juvena Therapeutics co-founder, director and executive adviser; formerly the company's chief executive. Research background in aging and degenerative disease biology informs its regenerative therapeutics platform.

Juvena Therapeutics board observer and scientific advisory board chairman, with earlier research sciences leadership at Merck.

Juvena Therapeutics board observer representing Mubadala Capital, explicitly listed in the current governance directory.

Juvena Therapeutics board observer representing Manta Ray, explicitly listed in the current governance directory.

Juvena Therapeutics board observer representing Horizons Ventures, explicitly listed in the current governance directory and named in its 2022 Series A announcement.

Vengadeshprabhu Karuppa Gounder is listed by Juvena Therapeutics as Senior Scientist II - Pharmacology, supporting its scientific discovery and operations team.

Ritwik Datta is listed by Juvena Therapeutics as Senior Scientist I, supporting its scientific discovery and operations team.

Sharon Louie is listed by Juvena Therapeutics as Senior Scientist II - Pharmacology, supporting its scientific discovery and operations team.

Rohit Jadhav is listed by Juvena Therapeutics as Senior Scientist II, supporting its scientific discovery and operations team.

Mingyu Chung is listed by Juvena Therapeutics as Senior Scientist I - Single Cell Genomics, supporting its scientific discovery and operations team.

Zhi Zheng is listed by Juvena Therapeutics as Scientist I, supporting its scientific discovery and operations team.

Danielle Yi is listed by Juvena Therapeutics as Scientist I, supporting its scientific discovery and operations team.

Trang Vuong is listed by Juvena Therapeutics as Scientist I, supporting its scientific discovery and operations team.

Munir Yousef is listed by Juvena Therapeutics as Senior Bioinformatics Analyst, supporting its scientific discovery and operations team.

Ashil Koranne is listed by Juvena Therapeutics as Associate Scientist, supporting its scientific discovery and operations team.

Megan Smith is listed by Juvena Therapeutics as Associate Scientist, supporting its scientific discovery and operations team.

Annie Yang is listed by Juvena Therapeutics as Senior Research Associate, supporting its scientific discovery and operations team.

Sarah Tang is listed by Juvena Therapeutics as Senior Research Associate, supporting its scientific discovery and operations team.

Jonathan Gaffney is listed by Juvena Therapeutics as Research Associate, supporting its scientific discovery and operations team.

Jamie Romero is listed by Juvena Therapeutics as Associate Director, Operations, supporting its scientific discovery and operations team.

Theodore Yu is listed by Juvena Therapeutics as Research Associate, supporting its scientific discovery and operations team.

Natalie Ploof is listed by Juvena Therapeutics as Lab Manager, supporting its scientific discovery and operations team.

Jefferson Life Sciences strategic adviser and biotechnology innovation executive. Previously led external innovation at Johnson & Johnson and has experience connecting startups, academic research and pharmaceutical partnerships.

Jefferson Life Sciences strategic adviser and Sanofi Ventures managing director, with earlier corporate development experience at Translate Bio and venture investment experience at Atlas Venture.

Jefferson Life Sciences strategic adviser and Mubadala Capital biotechnology investment partner. Previously held investment roles at RA Capital and Longitude Capital and helped build Epirium Bio.

Jefferson Life Sciences strategic adviser, Case Western Reserve University School of Medicine dean and regenerative medicine researcher with hematological oncology expertise.

Jefferson Life Sciences strategic adviser and medical technology executive with leadership experience at Cairdac, SamanTree Medical, Anaconda Biomed and SoniVie.

Jefferson Life Sciences strategic adviser and MIT professor specializing in biomedical engineering and cancer nanomedicine. A physician and engineer who directs MIT's Marble Center for Cancer Nanomedicine.

Jefferson Life Sciences senior associate with biotechnology investment and research experience at William Blair and Cleveland Clinic Ventures. Earned a life sciences doctorate at Northwestern University, studying reproductive organ-on-a-chip models.

Jefferson Life Sciences investment analyst with a Yale doctorate in cellular and molecular physiology, researching visual neuroscience and ophthalmology. Previously a Canaan-Yale Fellow on Canaan Partners' healthcare investing team.

Jefferson Life Sciences managing partner and biotechnology entrepreneur. Previously president and chief business officer at Satellite Bio and a founding team member at Valo Health, with company creation experience at Flagship Pioneering.

Life sciences investment firm within Jefferson River Capital, launched in 2025 and based in New York. Invests in therapeutic platforms from early development through commercialization, using flexible private and public investment structures. Its portfolio includes AI-enabled regenerative biologics, precision ophthalmology and neuroscience drug development.

Cavalry Biosciences develops medicines that direct the regenerative effects of insulin-like growth factor 1 (IGF-1) to specific tissues. Its antibody-biologic conjugate platform combines engineered IGF-1 with tissue-targeting antibodies. Investigational programmes include CAV-011 for corneal regeneration, CAV-033 for skeletal muscle and CAV-044 targeting Schwann cells to promote remyelination in peripheral neuropathies.

Prudentia Sciences develops an AI platform for scientific due diligence and valuation of drug assets. It combines clinical, regulatory and commercial evidence with scientific evaluation frameworks and financial models to help pharmaceutical companies, biotechnology companies and investors assess medicines for licensing, acquisition and investment. The platform supports evidence provenance and human review of AI-generated evaluations.

Camille Samuels is a healthcare venture investor named on Mission Bay Capital’s outside investment advisory committee. Its undated directory identifies her Venrock affiliation; Venrock’s2016 primary interview confirms she joined in2014 and discusses her work with life-science entrepreneurs and longevity science. These source-qualified advisory and historical affiliations are distinguished from Mission Bay employment or an inferred personal investment.

Mary Lynne Hedley joined Lilly’s board in 2022. She is a senior scientific fellow at the Broad Institute and a Third Rock Ventures venture partner. She co-founded TESARO in 2010 and served as president and chief operating officer before its 2019 acquisition by GSK.

Physician and drug developer formerly serving as Merida Biosciences CMO and Cerevel Therapeutics development executive.

Biotechnology entrepreneur, also known as Ned David, who co-founded Syrrx, Achaogen, Kythera, UNITY and Jupiter Bioventures.

Draig Therapeutics founder and head of biology, and Cardiff University Medicines Discovery Institute director. Specializes in GABA receptor biology, neuroscience drug discovery and human target engagement.

Draig Therapeutics chief medical officer and physician with neuroscience clinical development and regulatory experience. Previously held senior clinical development roles at Bristol Myers Squibb and Karuna Therapeutics.

Draig Therapeutics senior vice president of business operations and chief of staff. Previously a founding team member and strategic operations leader at Vigil Neuroscience, with experience at Ipsen, Teva and investment banks.

Draig Therapeutics senior vice president of program leadership and portfolio management. Neuropsychologist with clinical development experience at Convergence Pharmaceuticals and Eliem Therapeutics, where she served as chief development officer.

Draig Therapeutics senior vice president of people and culture. Has biotechnology and pharmaceutical talent leadership experience at Marengo, Allena, Theseus and Agenus, and a sociology doctorate from the Polish Academy of Sciences.

Draig Therapeutics senior director of finance. Previously held financial leadership roles at Summit Therapeutics and Gylden Pharma; a Fellow of the Association of Chartered Certified Accountants.

Draig Therapeutics president and chief executive. Previously founded and led Vigil Neuroscience through its IPO and acquisition by Sanofi in 2025; has business development experience at Ipsen, Teva and Dyax.

Draig Therapeutics director of corporate development and founding team member since 2024. Previously worked on biotechnology company creation at SV Health Investors and business development at Quell Therapeutics.

Douglas Williams serves as Chairman of the Board at CAMP4 Therapeutics. Biopharmaceutical executive and chairman of both CAMP4 and Draig Therapeutics. Previously held senior research leadership roles at Sana Biotechnology and Biogen and led Codiak BioSciences and ZymoGenetics.

Draig Therapeutics director representing ICG and former Draig chief medical officer, as identified in its launch announcement. Samantha Budd Haeberlein is an ALZpath director and neuroscience drug development executive. Her career includes neurodegeneration leadership at Biogen and earlier research and development roles at AstraZeneca.

Draig Therapeutics director representing SR One, listed in the company's current public directory.